Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
22.49
-1.10 (-4.68%)
Market open: Aug 12, 2026, 2:37 PM EDT
23.73
+0.14 (0.61%)
Previous after-hours: Aug 11, 2026, 7:36 PM EDT
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. Jean-Paul Kress M.D. | Chairman, President & CEO |
| Dr. Jeremy Sokolove M.D. | Chief Medical Officer |
| Dr. Navid Z. Khan Ph.D. | Chief Medical Affairs Officer |
| Dr. Robert Ang M.B.A., M.D., MBBS | Strategic Advisor |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board |
| Mr. Dallan Murray | Chief Commercial Officer |
| Mr. Sandesh Mahatme L.L.M. | Chief Business Officer & CFO |
| Ms. Adi Osovsky | General Counsel |
| Ms. Carol Lincoln CCP | Head of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-08-11 | 10-Q | vor-20260630.htm |
| 2026-07-07 | 8-K | vor-20260706.htm |
| 2026-06-12 | 8-K | vor-20260611.htm |
| 2026-06-08 | 8-K | vor-20260608.htm |
| 2026-05-13 | 10-Q | vor-20260331.htm |
| 2026-05-04 | CORRESP | filename1.htm |
| 2026-04-27 | S-3 | d27587ds3.htm |
| 2026-04-27 | DEFA14A | vor-20260422.htm |
| 2026-04-27 | ARS | vor_10-k_ars_2026_-_4.27.pdf |
| 2026-03-30 | S-8 | vor-20260327.htm |